Latest Living Cell Technologies Limited (LVCLF) He
Post# of 3
'First-in-man' Implant of Regenerative Cell Therapy in Parkinson's Disease
PR Newswire - Thu Sep 19, 9:36PM CDT
Living Cell Technologies Limited (LCT) today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL(R) - a potential treatment for Parkinson's disease.
Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Huntington's Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Huntington's Disease
M2 - Thu Sep 05, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6nbttk/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Huntington's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. Huntington's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Huntington's Disease. - A review of the Huntington's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Huntington's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 - ACADIA Pharmaceuticals Inc. - Accera, Inc. - Auspex Pharmaceuticals - BrainStorm Cell Therapeutics Inc. - Ceregene, Inc. - CrystalGenomics, Inc. - GW Pharmaceuticals plc - Galenea Corp. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Ipsen S.A. - Isis Pharmaceuticals, Inc. - KineMed, Inc. - Living Cell Technologies Limited - Neuralstem, Inc. - Omeros Corporation - Oryzon - Pfizer Inc. - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - SCYNEXIS, Inc. - Siena Biotech S.p.A. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - The Avicena Group, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - Vybion, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/6n...untingtons About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Huntington's Disease - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:33AM CDT
Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2013" report to their offering. 'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indicatio
Hearing Disorders - Pipeline Review, H2 2012
M2 - Thu Jan 17, 3:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/9dlpw7/hearing_disorders) has announced the addition of Global Markets Direct's new report "Hearing Disorders - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Hearing Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hearing Disorders. Hearing Disorders - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Hearing Disorders. - A review of the Hearing Disorders products under development by companies and universities/research institutes based